Welcome to our dedicated page for Kewaunee Scienti SEC filings (Ticker: KEQU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Kewaunee Scientific Corporation’s (NASDAQ: KEQU) SEC filings, allowing investors and researchers to review the company’s official regulatory disclosures. Kewaunee files reports and current event disclosures with the U.S. Securities and Exchange Commission as a public company listed on The Nasdaq Global Market.
In these filings, users can find quarterly and annual financial information, including discussions of segment performance for the domestic, international, and corporate segments. The company also explains its use of non-GAAP measures such as EBITDA, Segment EBITDA, Adjusted EBITDA, adjusted net earnings, and adjusted net earnings per share, and provides reconciliations to the most comparable GAAP measures.
Kewaunee’s Form 8-K current reports cover topics such as quarterly and annual results, amendments to bylaws, board appointments, annual meeting outcomes, and the timing of earnings releases. Proxy materials, such as the company’s definitive proxy statement, describe matters submitted to shareholders, including director elections, auditor ratification, advisory votes on executive compensation, and the frequency of such advisory votes.
Filings also document capital markets and governance actions, including details of share repurchase program approvals or amendments, loan agreements and related disclosures, and information about non-employee director compensation and committee assignments. Together, these documents provide a structured view of Kewaunee’s financial condition, governance framework, and significant corporate events.
On Stock Titan, KEQU filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered summaries highlight key points from long-form documents, helping users quickly understand the main changes, financial metrics, and governance decisions without reading every page of each filing.
Kewaunee Scientific Corporation’s President and CEO, Thomas David Hull III, who is also a director, reported a sale of company stock. On 01/07/2026, he sold 2,177 shares of Common Stock, reported at a weighted average price of $37.5 per share. The shares were sold in multiple trades at prices ranging from $37.21 to $37.54. After this transaction, he beneficially owns 33,000 shares of Kewaunee Scientific common stock directly.
Kewaunee Scientific insider activity shows its President and CEO, who also serves as a director, reported a stock sale. On 12/17/2025, the reporting person sold 1,000 shares of Kewaunee Scientific common stock at a price of $39 per share. After this transaction, the insider beneficially owns 37,719 shares directly.
Kewaunee Scientific reported revenue of
Gross margin was
Order backlog was
Kewaunee Scientific Corporation filed a Form 8-K to let investors know when its next financial results will be issued. The company plans to release its second quarter fiscal 2026 earnings on December 10, 2025. This notice is an administrative update and does not include any financial results or guidance. The related earnings press release is identified as Exhibit 99.1 to the report.
Donald T. Gardner III, Chief Financial Officer and director, reported a sale of 3,000 shares of Kewaunee Scientific Corp (KEQU) on
Form 144 notice for Kewaunee Scientific Corp. (ticker KEQU) reports a proposed sale of 3,000 common shares through Fidelity Brokerage Services LLC with an indicated aggregate market value of
Elizabeth D. Phillips, listed as a director and Vice President - Human Resources of Kewaunee Scientific Corp (KEQU), reported insider sales on 10/02/2025. The filing shows a sale of 6,877 shares at a weighted-average price of $43.20 (price range $43.05–$43.95), followed by an additional sale of 3 shares at $44.20. After the transactions the reporting person beneficially owned 8,251 shares and then 8,248 shares (direct ownership). The Form 4 was signed by an attorney-in-fact, Donald T. Gardner III. The filer also states availability of per-price purchase breakdown upon request.
Kewaunee Scientific director and President/CEO Thomas David Hull III reported a sale of 1,000 shares of the company's common stock on 10/01/2025 at a weighted average price of $43.09 per share, with the reported price range between $43.00 and $43.22. Following the sale, Mr. Hull beneficially owns 38,719 shares. The Form 4 was signed by an attorney-in-fact on 10/02/2025. The filing includes a statement that the reporting person will provide, upon request, the number of shares bought at each separate price within the disclosed range.
Kewaunee Scientific Corp (KEQU) filed a Form 144 reporting a proposed sale of 6,880 shares of common stock to be sold through Ameriprise Financial Services, LLC on 10/01/2025. The filing states an aggregate market value of $293,432.00 and lists 2,865,694 shares outstanding. The securities were acquired on 10/01/2025 as equity compensation from Kewaunee Scientific Corporation, with payment recorded as equity compensation on the same date. The filer reports no securities sold in the past three months and includes the standard signature representation that no undisclosed material adverse information is known.
KEWAUNEE SCIENTIFIC CORP (/DE/, KEQU) reporting person Thomas David Hull III, who serves as President, CEO and a director, reported a sale of common stock on 09/29/2025. The Form 4 shows 1,854 shares were sold at a weighted average price of $43.42, with the trade price range disclosed as $43.00 to $43.85. After the sale, Hull beneficially owns 39,719 shares, held directly. The form was signed by an attorney-in-fact on 10/01/2025. The filing includes an undertaking to provide detailed per-price purchase information on request.
FAQ
What is the current stock price of Kewaunee Scienti (KEQU)?
What is the market cap of Kewaunee Scienti (KEQU)?
